# Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

> **NCT04781413** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Stage IIIC Gastric Cancer

## Interventions

- **DRUG:** Nab-PTX, Sintilimab, S-1

## Key facts

- **NCT ID:** NCT04781413
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2021-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781413, "Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04781413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*